Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib-Reference-Cited by-同舟云学术

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Published:2013-03-14 Issue:11 Volume:121 Page:1961-1967
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Richardson Paul G.¹,Siegel David²,Baz Rachid³,Kelley Susan L.⁴,Munshi Nikhil C.¹,Laubach Jacob¹,Sullivan Daniel³,Alsina Melissa³,Schlossman Robert¹,Ghobrial Irene M.¹,Doss Deborah¹,Loughney Nora¹,McBride Laura²,Bilotti Elizabeth²,Anand Palka²,Nardelli Lisa³,Wear Sandra⁴,Larkins Gail⁵,Chen Min⁵,Zaki Mohamad H.⁵,Jacques Christian⁵,Anderson Kenneth C.¹

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA;

2. Hackensack University Medical Center, Hackensack, NJ;

3. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

4. Multiple Myeloma Research Consortium, Norwalk, CT; and

5. Celgene Corporation, Summit, NJ

Abstract

Key Points Pomalidomide with/without dexamethasone has promising activity and manageable toxicity in relapsed and refractory multiple myeloma patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/11/1961/1363891/1961.pdf

Reference30 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies.;Kumar;Blood,2008

2. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.;Lacy;J Clin Oncol,2009

3. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.;Kumar;Leukemia,2012

4. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.;Sinha;Leukemia,2012

5. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.;Lacy;Blood,2011

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pomalidomide Use and Kidney Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study;Clinical Lymphoma Myeloma and Leukemia;2024-07

2. Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma;Cancers;2024-03-15

3. Pomalidomide Improves Motor Behavioral Deficits and Protects Cerebral Cortex and Striatum Against Neurodegeneration Through a Reduction of Oxidative/Nitrosative Damages and Neuroinflammation After Traumatic Brain Injury;Cell Transplantation;2024-01

4. Pomalidomide Use and Kidney Outcomes in Patients with Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study;2024

5. Помалидомид в терапии рецидивирующей/рефрактерной множественной миеломы;Journal of Modern Oncology;2023-08-10